BUZZ-Australia's Neuren Pharmaceuticals extends plunge on regulatory hurdles
Reuters
Feb 05
BUZZ-Australia's <a href="https://laohu8.com/S/NEU.AU">Neuren Pharmaceuticals</a> extends plunge on regulatory hurdles
** Shares of Neuren Pharmaceuticals NEU.AX plunges as much as 10.7% to A$13.06
** Biotech says FDA will only provide written responses for NNZ-2591 drug development meetings, not face-to-face discussions as requested
** Drug targets hypoxic ischemic encephalopathy and Pitt Hopkins syndrome
** Stock fell 10% on Feb 3 on setback for Rett treatment drug application from European regulator, trading halt on Feb 4 pending FDA update
(Reporting by Nichiket Sunil in Bengaluru)
((Nichiket.Sunil@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.